Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0328 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0296 | 0.8746 | 0.8746 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0328 | 1 | 1 |
Brugia malayi | transcriptional regulator, Sir2 family protein | 0.0296 | 0.8746 | 0.8746 |
Echinococcus granulosus | NAD dependent deacetylase sirtuin 1 | 0.0328 | 1 | 1 |
Mycobacterium ulcerans | NAD-dependent deacetylase | 0.0076 | 0 | 0.5 |
Entamoeba histolytica | Sir2 family transcriptional regulator, putative | 0.0296 | 0.8746 | 1 |
Trypanosoma cruzi | Silent information regulator 2 related protein 1 | 0.0296 | 0.8746 | 1 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.0328 | 1 | 1 |
Loa Loa (eye worm) | transcriptional regulator | 0.0296 | 0.8746 | 0.8746 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0296 | 0.8746 | 0.8746 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.0296 | 0.8746 | 0.8746 |
Loa Loa (eye worm) | hypothetical protein | 0.0252 | 0.6973 | 0.6973 |
Echinococcus multilocularis | chromatin regulatory protein sir2 | 0.0296 | 0.8746 | 0.8746 |
Plasmodium falciparum | transcriptional regulatory protein sir2b | 0.0076 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0328 | 1 | 1 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0208 | 0.5246 | 0.5 |
Trypanosoma brucei | Silent information regulator 2 related protein 1 | 0.0296 | 0.8746 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0208 | 0.5246 | 0.5246 |
Entamoeba histolytica | Sir2 family transcriptional regulator, putative | 0.0296 | 0.8746 | 1 |
Mycobacterium tuberculosis | Transcriptional regulatory protein | 0.0076 | 0 | 0.5 |
Trypanosoma cruzi | Silent information regulator 2 related protein 1 | 0.0296 | 0.8746 | 1 |
Giardia lamblia | NAD-dependent histone deacetylase Sir2 | 0.0328 | 1 | 1 |
Toxoplasma gondii | histone deacetylase SIR2-like | 0.0076 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0076 | 0 | 0.5 |
Brugia malayi | ecdysteroid receptor | 0.0208 | 0.5246 | 0.5246 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.0296 | 0.8746 | 0.8746 |
Echinococcus granulosus | chromatin regulatory protein sir2 | 0.0296 | 0.8746 | 0.8746 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.0296 | 0.8746 | 0.8746 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0328 | 1 | 1 |
Plasmodium vivax | NAD-dependent deacetylase, putative | 0.0076 | 0 | 0.5 |
Echinococcus granulosus | NAD dependent deacetylase sirtuin 3 | 0.0296 | 0.8746 | 0.8746 |
Echinococcus multilocularis | NAD dependent deacetylase sirtuin 1 | 0.0328 | 1 | 1 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0328 | 1 | 1 |
Toxoplasma gondii | histone deacetylase SIR2 | 0.0076 | 0 | 0.5 |
Plasmodium falciparum | transcriptional regulatory protein sir2a | 0.0076 | 0 | 0.5 |
Echinococcus multilocularis | NAD dependent deacetylase sirtuin 3 | 0.0296 | 0.8746 | 0.8746 |
Leishmania major | silent information regulator 2, putative | 0.0296 | 0.8746 | 1 |
Mycobacterium ulcerans | Sir2-like regulatory protein | 0.0076 | 0 | 0.5 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.0296 | 0.8746 | 0.8746 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 250 ug ml-1 | Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability after 24 hrs by MTT assay | ChEMBL. | 23369537 |
MIC (functional) | = 125 ug ml-1 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition measured every 24 hrs by BACTEC radiosusceptibility assay | ChEMBL. | 23369537 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.